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Abstract
Background: C-reactive protein (CRP) is positively associated with risk for cardiovascular disease and all-cause
mortality. Some but not all randomized and non-randomized clinical trials found significant associations between
fenofibrate therapy and CRP but the direction and magnitude of the association varied across studies. The duration
of treatment, patient populations and sample sizes varied greatly, and most short-term studies (i.e., ≤ 12 weeks)
had fewer than 50 patients. In this study we meta-analyzed randomized clinical trials to determine the short-term
effect of fenofibrate on CRP.
Methods: Two reviewers independently searched PubMed and other online databases for short-term randomized
clinical trials that reported CRP concentrations before and after fenofibrate treatment. Of the 81 studies examined,
14 studies with 540 patients were found eligible. Data for the change in CRP and corresponding measures of
dispersion were extracted for use in the meta-analysis.
Results: The weighted mean CRP concentrations before and after fenofibrate therapy were 2.15 mg/L and 1.53
mg/L (-28.8% change), respectively. Inverse-variance weighted random effects meta-analysis revealed that short-
term fenofibrate treatment significantly lowers CRP by 0.58 mg/L (95% CI: 0.36-0.80). There was significant
heterogeneity between studies (Q statistic = 64.5, P< 0.0001, I
2 = 79.8%). There was no evidence of publication bias
and sensitivity analysis revealed that omitting any of the 14 studies did not lead to a different conclusion from the
overall meta-analysis result.
Conclusion: Short-term treatment with fenofibrate significantly lowers CRP concentration. Randomized trials that
will recruit patients based with high baseline CRP concentrations and with change in CRP as a primary outcome
are needed.
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1. Introduction
C-reactive protein (CRP), a nonspecific marker of
inflammation, is a predictor of incident cardiovascular
events and mortality [1-5]. Although the exact mechan-
ism through which CRP leads to increased risk for
adverse cardiovascular events is unknown, many studies
indicate that reducing serum CRP concentration leads
to significant benefits with regard to the future cardio-
vascular events [6,7]. Whether the reduction in events is
directly due to the reduction in CRP or due to the con-
comitant improvement in lipid profiles remains to be
elucidated.
In addition to genetic determinants [4,8], other factors
such as age, race, gender, BMI, smoking, alcohol use, diet
and exposure to pollutants are known to affect CRP con-
centrations in serum [4,9]. Other than genetic factors, age,
race and gender, all the other risk factors for elevated
serum CRP are potentially modifiable and they provide an
opportunity for intervention. Indeed, studies have shown
that exercise, dietary modifications as well as other lifestyle
changes lead to a reduction in serum CRP levels [10,11].
Despite this apparent benefit, exercise, dietary and lifestyle
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any medium, provided the original work is properly cited.changes have only proven to be effective on a short-term
basis because of poor compliance as people tend to revert
to their old habits [10]. Lifestyle changes require highly
motivated individuals in order to attain long-term benefits,
an attribute that limits their application in management of
chronic inflammation.
Pharmacologic interventions may provide an effective
strategy to manage elevated CRP concentrations, especially
among individuals who are not willing or are unable to
adhere to dietary and other lifestyle changes [4]. Statins
such rosuvastatin or simvastatin are effective in lowering
serum CRP concentrations [4,9,12-14]. Other studies have
shown that niacin, fish oil esters and fenofibrate individu-
ally or in combination have an effect on serum CRP con-
centrations [15]. However, the results from fenofibrate
trials have been inconsistent, with some studies indicating
a reduction [13,15] while others indicating no change or
an increase in CRP [16-18]. A number of factors may
explain this apparent inconsistency in outcome. First,
most of the studies may have been underpowered (typi-
cally < 50 patients per study). Second, the dose and formu-
lation of fenofibrate varied greatly. Although the different
formulations could have been metabolically equivalent
regardless of the dose, the associations between fenofibrate
and CRP could be further complicated by the variable
length of follow-up that ranges from about three weeks to
years in studies such as the Fenofibrate Intervention and
Event Lowering in Diabetes (FIELD) study [16]. Studies
with longer durations could have been influenced by
extraneous unmeasured effects such as changes in body
weight and other lifestyle attributes. Lastly, fenofibrate stu-
dies have used diverse participant pools with varied base-
line serum CRP concentrations. Muhlestein et al. [13]
have shown that individuals with high baseline CRP con-
centrations tend to experience a greater reduction in CRP
than those with relatively low baseline values. Thus, it is
possible that the benefit of fenofibrate is greater in people
with elevated serum CRP concentrations in comparison to
people with low serum CRP concentrations.
The aim of this study is to determine, through a meta-
analysis, the effect of fenofibrate on serum CRP and to
estimate the size of this effect in short-term trials (12
w e e k so rl e s s )s i n c et h e ya r eu n l i k e l yt ob ec o n f o u n d e d
by long-term changes in body weight and behaviors
such as diet and physical activity.
2. Methods
2.1 Literature searches
We conducted a comprehensive review of studies on the
relation between fenofibrate and CRP that were pub-
lished between 1966 and March 31, 2011. Using
PubMed as the primary database, we searched for the
following terms: “fenofibrate” and ("CRP” or “hsCRP” or
“C-Reactive Protein” or “high-sensitivity C-Reactive
Protein”). Search of additional databases including Goo-
gle Scholar yielded studies that were already in PubMed.
All full text articles that met the criteria below were
independently retrieved and reviewed for study design
and availability of relevant statistics by two reviewers (JY
and JK). When duplicate studies were found, only the
most complete article was included.
2.2 Selection criteria
Randomized clinical trials that met the following inclu-
sion criteria were selected for the meta-analysis:
￿ Fenofibrate was one of the randomized treatment
arms.
￿ Fenofibrate treatment lasted 3-12 weeks (short-
term trial). Since most studies did not have a pla-
cebo and CRP can be affected by variables such as
change in body weight, we restricted the analyses to
short-term randomized studies.
￿ Findings were reported in the English language.
￿ Relevant statistics for imputing or computing the
mean change and corresponding standard error were
reported.
Any disagreements on the inclusion of identified stu-
dies by the two reviewers (JY and JK) were resolved by
discussion or consensus involving a third reviewer (EK).
The kappa statistic for the agreement between the first
two reviewers was computed.
2.3 Data extraction
Two reviewers (JY and JK) independently extracted data
from agreed upon studies using a standard data collection
form. Characteristics of each study were recorded. These
included the first author, country, publication year, dose
and duration of fenofibrate treatment, sample size of feno-
fibrate treatment arm, patient population, comparison
group, mean and standard error of the change in CRP
concentration before and after fenofibrate treatment. Data
sets extracted by the two reviewers were compared.
For some studies that reported median CRP concen-
trations before and after fenofibrate treatment, we
imputed the mean change in CRP concentrations as the
difference between median CRP concentrations before
and after fenofibrate treatment. For some studies that
did not report the standard error of the change in CRP
concentration, we used the formulas below from the
Cochrane’s handbook for meta-analysis by Higgins et al.
[19] to compute or impute the standard error:
￿ If the standard deviation (SD) was reported, we
computed the standard error (SE) using
SE=S D /
√
N
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statistic as t = Tinv (p-value, N-1), where Tinv(p-
value, N-1) is a function that returns value t such
that P(|X∥ > t) = p-value and X is a random variable
that follows a t-distribution with N-1 degrees of
freedom. The standard error was then obtained by
dividing the mean change (MC) by the t value (SE =
MC/t)
￿ If neither the SD of the mean change nor the p-
value was reported but the standard errors of CRP
concentration before and after treatment were
reported, we imputed the SE of the change using a
correlation coefficient from other studies using the
formula below [19]:
corr =
SD2
Before + SD2
After − SD2
Change
2 × SDBefore × SDAfter
Using the sample size from each study as the weight,
we computed a pooled correlation coefficient which is
the weighted sum of correlation coefficients from all
studies with enough information reported and then
imputed the standard deviation of mean change as fol-
lows:
SDChange =

SD2
Before + SD2
After − 2 × Corr × SDBefore × SDAfter
2.4 Meta-analysis
MIX software version 1.7 [20,21] was used for all ana-
lyses including generation of the Forest plot, Funnel plot
and sensitivity analysis plot. To account for both within-
study and between-study variation in the meta-analysis
we used a random effects model with the inverse of the
variance as the weight for each study. We tested for het-
erogeneity in the studies using Cochran’s Q statistic and
calculated I
2, the percentage of the total variability in
effect estimates among trials that is due to heterogeneity
rather than chance. The summary effect of each study
and the pooled effect from all studies are reported as
point estimates and corresponding 95% confidence
intervals on a Forest plot. To assess the potential for
publication bias we used a Funnel plot. To evaluate
whether an individual study had undue influence on the
overall meta-analysis result, we performed sensitivity
analyses by omitting one of the studies at a time and
determining whether statistical conclusion remained the
same. Studies were excluded one by one in the order in
which they appear in the Forest plot. The study by Kim
et al was excluded first and the study by Hogue et al
was excluded last. To compute the number of null stu-
dies needed to invalidate the observed association from
the meta-analysis (i.e., fail-safe N), we used formula
number 3 from Orwin [22]. We computed fail-safe Ns
for the small and medium Cohen’s criterion values (dc)
of 0.2 and 0.5, respectively.
3. Results
3.1. Literature searches
We identified a total of 81 citations in PubMed. As
shown in Figure 1, 77 of the studies were published in
English, from which we excluded 9 that were not done
in humans, 21 that were review articles or not clinical
trials and 6 whose full texts we could not obtain. Finally,
41 articles were fully reviewed for study design and rele-
vant statistics. Based on our criteria for study selection,
5 of these were not randomized clinical trials, 4 were
long-term studies (> 12 weeks of fenofibrate treatment),
2 had populations that were not of interest given poten-
tial confounding by medications (e.g., steroids in rheu-
matoid arthritis), 4 did not report sufficient statistics for
our meta-analysis, one study was too short (lasted < 2
weeks), one reported statistics that seemed implausible
and 3 were duplicates. After all the exclusions, 14 stu-
dies with a total of 540 patients met our criteria for
inclusion in the meta-analys i sa ss u m m a r i z e di nF i g u r e
1 and Tables 1 and 2.
3.2. Efficacy
The weighted mean CRP concentrations before and
after fenofibrate therapy were 2.15 mg/L and 1.53 mg/L
(-28.8% change), respectively. As shown in Figure 2,
short-term treatment with fenofibrate significantly low-
ers CRP by 0.58 mg/L (95% CI: 0.36-0.84 mg/L). There
was significant heterogeneity (Q statistic = 64.5, P <
0.0001) in the studies. The high estimated I
2 value
(79.8%) confirmed the need to use a random-effects
meta-analysis model as we did in this study.
Studies included in the current analyses were con-
ducted in various parts of the world and included parti-
cipants that varied in their baseline CRP concentrations.
We thus reanalyzed the data after stratifying studies by
region or baseline CRP concentrations. Seven of the stu-
dies were from Europe, 4 from North America and 3
from Asia. The resultant pooled estimates (95% CI) for
CRP reduction were -0.72 (-1.01, -0.42; P < 0.0001) for
Europe, -0.61 (-1.14, -0.08; P = 0.02) for North America
and -0.30 (-0.46, -0.14; P = 0.0002) for Asia. In agree-
ment with previous studies [13], we considered a base-
line CRP ≥ 2.0 mg/L to be high. We then carried out an
analysis restricted to the studies that had participants
with median/mean baseline CRP ≥ 2.0 mg/L [13]. As
expected, we observed a larger decrease in CRP follow-
ing treatment in individuals with high baseline CRP.
The pooled estimate from 8 studies with high CRP was
-0.72 (95% CI: -1.12, -0.32) mg/L compared to 0.58
(95% CI: 0.36-0.80) mg/L in analyses that pooled all the
14 studies.
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The Funnel plot (Figure 3) is fairly symmetric, suggest-
ing no evidence for publication bias.
3.4. Sensitivity analysis
Sensitivity analysis (Figure 4) suggests that by excluding
any of the 14 studies from the meta-analysis the esti-
mated effect will still be within the 95% CI of the esti-
mated effect under the null hypothesis and will not get
a different conclusion from the overall meta-analysis
result.
3.5. Kappa and fail-safe N
The Kappa for agreement in selecting studies for inclu-
sion in the meta-analysis was 0.47. The fail-safe Ns for
the small and medium Cohen’s criterion values were 64
and 17 studies, respectively.
4. Discussion
The results from the current meta-analysis show that
short-term treatment with fenofibrate leads to a significant
reduction in serum CRP concentrations (0.58 mg/L or
28.8% reduction, P < 0.0001) and that the magnitude of
the reduction is significantly heterogeneous across studies
(Q = 64.5; P < 0.0001). Using the random effects model,
the pooled mean absolute reduction of serum CRP was
0.58 mg/L (95% CI: 0.36-0.80) with a Z-score for the over-
all effect of 12.3 (P < 0.0001). The mean reduction in CRP
varied by region and was greatest for studies that had
higher baseline CRP concentrations. Sensitivity analyses
show that the overall effect is robust since none of the stu-
dies has an undue effect on our study findings and stratifi-
cation by region did not change the conclusion from this
study. Our findings do not seem to be affected by publica-
tion bias as shown by the Funnel plot.
14 short-term randomized clinical trials selected and 
included in the meta-analysis (540 patients) 
28 excluded:
x  Not a randomized clinical trial (n=5) 
x  No fenofibrate alone as a treatment arm of the 
trial (n=8) 
x  Not a short-term trial i.e., duration of 
treatment >12 weeks (n=4) 
x  Duration too short i.e., <2 weeks (n=1) 
x  Study population not of interest (n=2) 
x  Relevant statistics missing (n=4) or implausible 
(n=1)
x  Duplicates (n=3) or two studies reported in one 
paper
41 Clinical trial articles selected for full review to 
check study design and statistics 
40 excluded: 
x  Not in English (n=4) 
x  Not in humans (n=9) 
x  Not a clinical trial (n=21) 
x  Full text not available (n=6) 
81 Citations identified from PubMed 
Figure 1 Flow chart showing how studies were selected for inclusion in the meta-analysis.
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Page 6 of 11To date, there is no published meta-analysis on the
relation between fenofibrate and CRP. In agreement
with our meta-analytic findings, many short-term stu-
dies have reported a significant reduction in serum CRP
following fenofibrate therapy [23-26]. In support of our
finding that fenofibrate reduces CRP concentrations in
serum, there are mechanistic human studies showing
that fenofibrate therapy reduces the production of
inflammatory cytokines by monocytes [14]. Other short-
term studies have reported a non-significant reduction
in serum CRP concentration following administration of
fenofibrate [27]. Some long-term studies have also
reported significant reductions in serum CRP following
Figure 2 Forrest plot showing the change in C-reactive protein concentrations following treatment with fenofibrate.
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Figure 3 Funnel plot showing no evidence for publication bias.
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Figure 4 Effect of excluding one study at time on the overall
estimated effect of fenofibrate on C-reactive protein
concentrations. The solid line indicates the pooled estimate while
the dashed lines indicate the 95% confidence intervals. The studies
were excluded from the analysis in the order they appear in the
Forest plot (Figure 2) i.e., the study by Kim et al was excluded first
and the study by Hogue et al was excluded last.
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Page 7 of 11fenofibrate therapy [28] while others reported a non-sig-
nificant reduction in serum CRP concentrations [29].
However, not all studies investigating the relationship
between fenofibrate and serum CRP have reported find-
ings that agree with our findings. Some short-term [17]
and long-term [16] studies such the FIELD study have
reported an increase in serum CRP following fenofibrate
therapy.
The reasons for the disparity in the response to fenofi-
brate, especially in short-term studies where correlates
of CRP such as BMI remain stable, remain obscure. One
possible reason for this apparent variability in study
findings is that many of the studies have had the disad-
vantage of having small sample sizes (usually < 50
patients) thus making their estimates of effect likely to
be unstable, especially if the baseline CRP concentra-
tions are very low. This disadvantage of small sample
sizes could have been overcome by the fairly large sam-
ple size of 540 patients in 14 studies used in the current
meta-analysis. Moreover, the estimated effect of fenofi-
brate on CRP is a weighted average, which gives a more
precise estimate than any of the individual studies upon
which the meta-analysis is based. Also, participants in
studies on fenofibrate and CRP were recruited based on
their triglyceride concentrations. Although most patients
with high triglycerides tend to have high CRP, this is
not always the case and may confound results given that
lipid-lowering drugs tend to lower CRP more among
individuals who have baseline CRP concentrations above
2 mg/L [13] and may increase CRP in patients with very
low baseline concentrations. Indeed our analyses
restricted to studies with CRP concentrations ≥ 2m g / L
showed that the reduction in CRP in this subset (-0.72;
95% CI: -1.12, -0.32 mg/L) was greater than that
observed when all studies are combined (0.58; 95% CI:
0.36-0.80 mg/L). We also observed regional differences
in CRP reduction. The reduction in CRP observed for
studies conducted in Europe was similar to that
observed for studies in North America but much greater
than that observed for studies conducted in Asia. The
reason is not clear but may in part reflect the differ-
ences in baseline CRP and small number of studies con-
ducted in Asia (n = 3) compared to those conducted in
Europe (n = 7) or North America (n = 4). However,
d e s p i t ev a r i a b i l i t yb yr e g i o n ,a l lt h et h r e ep o o l e de s t i -
mates indicate a significant reduction in CRP following
treatment with fenofibrate. Evaluation of the efficacy of
fenofibrate on serum CRP will require randomized stu-
dies that recruit patients with high baseline CRP con-
centrations e.g., ≥ 2 mg/L.
The other potential reason for the variability in find-
ings across studies could be the variation in the strength
of fenofibrate used. The dosage of fenofibrate used in
most short-term studies we reviewed varied from 145
mg/day [30,31] to 267 mg/day [32,33]. Furthermore, var-
ious formulations (e.g., micronized vs. non-micronized)
were used. Although, different formulations are expected
to be metabolically equivalent, this may not always be
the case given potential variability in adherence and
genetic effects on response to fenofibrate. Since fenofi-
brate acts mainly through binding onto peroxisome pro-
liferator-activated receptor-alpha [34], it is possible that
formulations that result in lower amounts of the avail-
able active form of fenofibrate will lead to different phy-
siological outcomes and this could explain the observed
inconsistencies across studies. In addition to the differ-
ences in dosage and/or formulations, most fenofibrate
studies on CRP either did not include a placebo arm or
used another lipid-lowering drug as the comparison
group. Since randomized placebo-controlled studies on
fenofibrate are very few, it is difficult to disentangle the
true effects of fenofibrate from those that are simply
due to regression to the mean, especially given the small
size of most short-term fenofibrate trials.
Another potential reason for the variability in the out-
come could be the study duration. There is evidence
that the effect of fenofibrate on clinical parameters may
not be complete within 3 weeks of treatment with feno-
fibrate (Kabagambe et al., unpublished findings) and this
period could be longer as shown in other studies [14].
Other unmeasured variables that influence serum CRP
concentrations could change during long-term follow-up
but most studies did not have a placebo arm to investi-
gate this effect. However, this was not the case in the
Helsinki arm of the Fenofibrate Intervention and Event
Lowering Diabetes (FIELD) trial which included a pla-
cebo and where individuals were randomized [16]. In
this study that included 170 patients with relatively low
CRP concentrations (median ≤ 1.8 mg/L), fenofibrate
therapy was associated with a 20.1% non-significant
increase in CRP (95% CI: -0.8 to 28.8%) over a 5-year
follow-up period [16]. Since most studies did not have a
placebo group we restricted our analyses to short-term
studies (≤ 12 weeks) to minimize potential changes in
CRP that are due to changes in patient characteristics
e.g., BMI.
Our findings present significant clinical implications in
the management of elevated serum concentrations of
CRP. To date, only one clinical trial (JUPITER) where
patients were recruited based on having high CRP concen-
trations (≥ 2 mg/L) has been reported [35]. This study [35]
showed that compared to the placebo, rosuvastatin low-
ered CRP by 37%, a magnitude higher than that observed
in the current meta-analysis (28.8% mean reduction) of
studies with a wide range of baseline CRP concentrations.
Whether the effect of fenofibrate among patients with
high CRP is comparable to that of resuvastatin is yet to be
established. Studies comparing other statins to fenofibrate,
Ye et al. Diabetology & Metabolic Syndrome 2011, 3:24
http://www.dmsjournal.com/content/3/1/24
Page 8 of 11showed that among patients with CRP > 2 mg/L, the
reduction in CRP due to fenofibrate (-19.0%) was compar-
able to that due to simvastatin (-24.8%) therapy [13]. In
another study [14] the reduction in CRP due to fenofibrate
therapy (23 ± 4%) was comparable to that by simvastatin
(20 ± 3%), but the patient populations in the two groups
were somewhat different with regard to their lipid profiles
at study entry. Most studies comparing fenofibrate to
other lipid-lowering medications were quite small in sam-
ple size (< 50 patients). Until equivalence studies with
rosuvastatin as a reference are done, it is plausible to have
rosuvastatin as the established approach for managing ele-
vated CRP concentrations. However, some patients experi-
ence adverse reactions following administration of statins
[36]. Fish oil or fish oil esters are the other option but
have side effects too such as undesirable fish odor or
increased risk for bleeding and in some studies, including
randomized trials, reduction in CRP was not attained [37].
Niacin is the other option and in one study [15] the mag-
nitude of reduction in CRP was higher than that of fenofi-
brate but as for some statins [38], use of niacin has been
associated with glucose dysregulation [15].
Our results confirm that fenofibrate is another feasible
alternative therapy in the short-term management of
CRP especially among patients who do not tolerate sta-
tins, fish oil products, niacin or are unable to adhere to
increased physical activity or healthy lifestyle changes.
Whether reduction of CRP will be observed among
patients with high baseline CRP and followed over a long
period as in the ACCORD (Action to Control Cardiovas-
cular Risk in Diabetes) study [39] is yet to be determined.
We acknowledge a number of limitations in our study.
First, we used secondary data and thus are unable to
rule out potential errors in the original studies. Such
errors, if existent, they could bias our conclusions but
the sensitivity analyses showed that the conclusion from
this meta-analysis is not sensitive to elimination of an
individual study. Secondly, although we have attempted
to explore publication bias as a potential explanation of
the findings, we did not find evidence for it. We believe
that publication bias is unlikely to have affected our
findings because standard inclusion and exclusion cri-
teria were used in all the studies thus making preferen-
tial exclusion/inclusion highly unlikely. Moreover, the
computed fail-safe N suggests that we would need 17-64
null studies to make the current meta-analysis show a
null association between fenofibrate and CRP.
5.0 Conclusion
We conclude that short-term treatment with fenofibrate
is an effective strategy in the management of elevated
CRP concentrations. Despite having significant heteroge-
neity in the studies analyzed, this meta-analysis has
shown a significant pooled mean reduction in serum
CRP of 0.58 mg/L (95% CI: 0.36-0.80; P < 0.0001). Our
findings have significant clinical implications in that
fenofibrate is an option for patients who cannot tolerate
statins, niacin or fish oil products and their derivatives.
Although, fenofibrate has not shown benefit on all-cause
mortality, it may be desirable to conduct a trial among
people with elevated CRP but who do not tolerate thera-
pies such as statins.
List of abbreviations
CRP: C-reactive protein; SD: Standard deviation; SE: Standard error.
Acknowledgements
This study is supported by grant # R21DK084560 from the National Institute
of Diabetes and Digestive and Kidney Diseases.
Author details
1Department of Epidemiology, University of Alabama at Birmingham,
Birmingham, AL, USA.
2Department of Biostatistics, University of Alabama at
Birmingham, Birmingham, AL, USA.
Authors’ contributions
EK conceived the idea. All authors refined the idea and JY and JK searched
and extracted data from PubMED. JY, JK and EK performed the analyses. JY
and JK drafted the manuscript. All authors edited various copies of the
manuscript and approved the final version.
Competing interests
The authors declare that they have no competing interests.
Received: 9 May 2011 Accepted: 22 September 2011
Published: 22 September 2011
References
1. Kabagambe EK, Judd SE, Howard VJ, Zakai NA, Jenny NS, Hsieh M,
Warnock DG, Cushman M: Inflammation biomarkers and risk of all-cause
mortality in the reasons for geographic and racial differences in stroke
cohort. American Journal of Epidemiology 2011, 174:284-292.
2. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A,
Hutchinson WL, Pepys MB: C-Reactive protein, a sensitive marker of
inflammation, predicts future risk of coronary heart disease in initially
healthy middle-aged men: results from the MONICA (Monitoring Trends
and Determinants in Cardiovascular Disease) Augsburg Cohort Study,
1984 to 1992. Circulation 1999, 99:237-242.
3. Marsik C, Kazemi-Shirazi L, Schickbauer T, Winkler S, Joukhadar C,
Wagner OF, Endler G: C-reactive protein and all-cause mortality in a large
hospital-based cohort. Clin Chem. United States 2008, 54:343-349.
4. Kones R: Rosuvastatin, inflammation, C-reactive protein, JUPITER, and
primary prevention of cardiovascular disease–a perspective. Drug Des
Devel Ther 2010, 4:383-413.
5. Jenny NS, Yanez ND, Psaty BM, Kuller LH, Hirsch CH, Tracy RP: Inflammation
biomarkers and near-term death in older men. Am J Epidemiol 2007,
165:684-695.
6. Kincl V, Panovsky R, Meluzin J, Semenka J, Groch L, Tomcikova D,
Jarkovsky J, Dusek L: Association between laboratory markers and
presence of coronary artery disease. Biomed Pap Med Fac Univ Palacky
Olomouc Czech Repub 2010, 154:227-233.
7. Shi B, Ni Z, Cai H, Zhang M, Mou S, Wang Q, Cao L, Yu Z, Yan Y, Qian J:
High-sensitivity C-reactive protein: an independent risk factor for left
ventricular hypertrophy in patients with lupus nephritis. J Biomed
Biotechnol 2010, 2010:373-426.
8. Brull DJ, Serrano N, Zito F, Jones L, Montgomery HE, Rumley A, Sharma P,
Lowe GD, World MJ, Humphries SE, Hingorani AD: Human CRP gene
polymorphism influences CRP levels: implications for the prediction and
pathogenesis of coronary heart disease. Arterioscler Thromb Vasc Biol.
United States 2003, 23:2063-2069.
Ye et al. Diabetology & Metabolic Syndrome 2011, 3:24
http://www.dmsjournal.com/content/3/1/24
Page 9 of 119. Ruckerl R, Greven S, Ljungman P, Aalto P, Antoniades C, Bellander T,
Berglind N, Chrysohoou C, Forastiere F, Jacquemin B, et al: Air pollution
and inflammation (interleukin-6, C-reactive protein, fibrinogen) in
myocardial infarction survivors. Environ Health Perspect 2007,
115:1072-1080.
10. Dutheil F, Lesourd B, Courteix D, Chapier R, Dore E, Lac G: Blood lipids and
adipokines concentrations during a 6-month nutritional and physical
activity intervention for metabolic syndrome treatment. Lipids Health Dis.
England 2010, 9:148.
11. Hermsdorff HH, Zulet MA, Puchau B, Martinez JA: Fruit and vegetable
consumption and proinflammatory gene expression from peripheral
blood mononuclear cells in young adults: a translational study. Nutr
Metab (Lond). England 2010, 7:42.
12. Ridker PM, Rifai N, Lowenthal SP: Rapid reduction in C-reactive protein
with cerivastatin among 785 patients with primary
hypercholesterolemia. Circulation 2001, 103:1191-1193.
13. Muhlestein JB, May HT, Jensen JR, Horne BD, Lanman RB, Lavasani F,
Wolfert RL, Pearson RR, Yannicelli HD, Anderson JL: The reduction of
inflammatory biomarkers by statin, fibrate, and combination therapy
among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes
and Combined Lipid Therapy Regimen) study. J Am Coll Cardiol 2006,
48:396-401.
14. Okopien B, Krysiak R, Kowalski J, Madej A, Belowski D, Zielinski M,
Herman ZS: Monocyte release of tumor necrosis factor-alpha and
interleukin-1beta in primary type IIa and IIb dyslipidemic patients
treated with statins or fibrates. J Cardiovasc Pharmacol. United States 2005,
46:377-386.
15. Wi J, Kim JY, Park S, Kang SM, Jang Y, Chung N, Shim WH, Cho SY, Lee SH:
Optimal pharmacologic approach to patients with hypertriglyceridemia
and low high-density lipoprotein-cholesterol: randomized comparison of
fenofibrate 160 mg and niacin 1500 mg. Atherosclerosis 2010, 213:235-240.
16. Hiukka A, Westerbacka J, Leinonen ES, Watanabe H, Wiklund O, Hulten LM,
Salonen JT, Tuomainen TP, Yki-Jarvinen H, Keech AC, Taskinen MR: Long-
term effects of fenofibrate on carotid intima-media thickness and
augmentation index in subjects with type 2 diabetes mellitus. J Am Coll
Cardiol 2008, 52:2190-2197.
17. Fegan PG, Shore AC, Mawson D, Tooke JE, MacLeod KM: Microvascular
endothelial function in subjects with Type 2 diabetes and the effect of
lipid-lowering therapy. Diabet Med. England 2005, 22:1670-1676.
18. Hogue JC, Lamarche B, Tremblay AJ, Bergeron J, Gagne C, Couture P:
Differential effect of atorvastatin and fenofibrate on plasma oxidized
low-density lipoprotein, inflammation markers, and cell adhesion
molecules in patients with type 2 diabetes mellitus. Metabolism. United
States 2008, 57:380-386.
19. Higgins JPT, Green S: Cochrane Handbook for Systematic Reviews of
Interventions Version 5.1.0 [updated March 2011]. The Cochrane
Collaboration. 2011 [http://www.cochrane-handbook.org].
20. Bax L, Yu L-M, Ikeda N, Tsuruta H, Moons K: Development and validation
of MIX: comprehensive free software for meta-analysis of causal
research data. BMC Medical Research Methodology 2006, 6:50.
21. Bax L: MIX 1.7: Comprehensive free soft ware for metaanalysis of causal
research data.[http://www.meta-analysis-made-easy.com/], (Last accessed:
August 16, 2011).
22. Orwin RG: A fail-safe N for effect size in meta-analysis. Journal of
Educational Statistics 1983, 8:157-159.
23. Ikewaki K, Tohyama J, Nakata Y, Wakikawa T, Kido T, Mochizuki S:
Fenofibrate effectively reduces remnants, and small dense LDL, and
increases HDL particle number in hypertriglyceridemic men-a nuclear
magnetic resonance study. J Atheroscler Thromb. Japan 2004, 11:278-285.
24. Pruski M, Krysiak R, Okopien B: Pleiotropic action of short-term metformin
and fenofibrate treatment, combined with lifestyle intervention, in type
2 diabetic patients with mixed dyslipidemia. Diabetes Care. United States
2009, 32:1421-1424.
25. Koh KK, Han SH, Quon MJ, Yeal Ahn J, Shin EK: Beneficial effects of
fenofibrate to improve endothelial dysfunction and raise adiponectin
levels in patients with primary hypertriglyceridemia. Diabetes Care. United
States 2005, 28:1419-1424.
26. Coban E, Ozdogan M, Yazicioglu G, Sari R: The effect of fenofibrate on the
levels of high sensitivity C-reactive protein in dyslipidaemic hypertensive
patients. Int J Clin Pract. England 2005, 59:415-418.
27. Phuntuwate W, Suthisisang C, Koanantakul B, Chaloeiphap P, Mackness B,
Mackness M: Effect of fenofibrate therapy on paraoxonase1 status in
patients with low HDL-C levels. Atherosclerosis. Ireland 2008, 196:122-128.
28. Zhu S, Su G, Meng QH: Inhibitory effects of micronized fenofibrate on
carotid atherosclerosis in patients with essential hypertension. Clin Chem.
United States 2006, 52:2036-2042.
29. Goto M: A comparative study of anti-inflammatory and antidyslipidemic
effects of fenofibrate and statins on rheumatoid arthritis. Mod Rheumatol
2010, 20:238-243.
30. Ansquer JC, Bekaert I, Guy M, Hanefeld M, Simon A: Efficacy and safety of
coadministration of fenofibrate and ezetimibe compared with each as
monotherapy in patients with type IIb dyslipidemia and features of the
metabolic syndrome: a prospective, randomized, double-blind, three-
parallel arm, multicenter, comparative study. Am J Cardiovasc Drugs. New
Zealand 2009, 9:91-101.
31. Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, Palumbo I,
D’Angelo A, Cicero AF: Fenofibrate, simvastatin and their combination in
the management of dyslipidaemia in type 2 diabetic patients. Curr Med
Res Opin 2009, 25:1973-1983.
32. Okopien B, Krysiak R, Herman ZS: Effects of short-term fenofibrate
treatment on circulating markers of inflammation and hemostasis in
patients with impaired glucose tolerance. J Clin Endocrinol Metab. United
States 2006, 91:1770-1778.
33. Broncel M, Cieslak D, Koter-Michalak M, Duchnowicz P, Mackiewicz K,
Chojnowska-Jezierska J: [The anti-inflammatory and antioxidants effects
of micronized fenofibrate in patients with visceral obesity and
dyslipidemia]. Pol Merkur Lekarski 2006, 20:547-550.
34. Keech AC, Mitchell P, Summanen PA, O’Day J, Davis TM, Moffitt MS,
Taskinen MR, Simes RJ, Tse D, Williamson E, et al: Effect of fenofibrate on
the need for laser treatment for diabetic retinopathy (FIELD study): a
randomised controlled trial. Lancet. England 2007, 370:1687-1697.
35. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ,
Koenig W, Libby P, Lorenzatti AJ, Macfadyen JG, et al: Reduction in C-
reactive protein and LDL cholesterol and cardiovascular event rates after
initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet
2009, 373:1175-1182.
36. Meier N, Nedeltchev K, Brekenfeld C, Galimanis A, Fischer U, Findling O,
Remonda L, Schroth G, Mattle HP, Arnold M: Prior statin use, intracranial
hemorrhage, and outcome after intra-arterial thrombolysis for acute
ischemic stroke. Stroke. United States 2009, 40:1729-1737.
37. Balk EM, Lichtenstein AH, Chung M, Kupelnick B, Chew P, Lau J: Effects of
omega-3 fatty acids on serum markers of cardiovascular disease risk: a
systematic review. Atherosclerosis 2006, 189:19-30.
38. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ,
Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, et al: Statins and risk of
incident diabetes: a collaborative meta-analysis of randomised statin
trials. Lancet 2010, 375:735-742.
39. Buse JB, Bigger JT, Byington RP, Cooper LS, Cushman WC, Friedewald WT,
Genuth S, Gerstein HC, Ginsberg HN, Goff DC Jr, et al: Action to Control
Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am
J Cardiol 2007, 99:21i-33i.
40. Kim CJ: Effects of fenofibrate on C-reactive protein levels in
hypertriglyceridemic patients. J Cardiovasc Pharmacol. United States 2006,
47:758-763.
41. Undas A, Celinska-Lowenhoff M, Domagala TB, Iwaniec T, Dropinski J,
Lowenhoff T, Szczeklik A: Early antithrombotic and anti-inflammatory
effects of simvastatin versus fenofibrate in patients with
hypercholesterolemia. Thromb Haemost. Germany 2005, 94:193-199.
42. Sebestjen M, Keber I, Zegura B, Simcic S, Bozic M, Fressart MM, Stegnar M:
Statin and fibrate treatment of combined hyperlipidemia: the effects on
some novel risk factors. Thromb Haemost. Germany 2004, 92:1129-1135.
43. Wang TD, Chen WJ, Lin JW, Cheng CC, Chen MF, Lee YT: Efficacy of
fenofibrate and simvastatin on endothelial function and inflammatory
markers in patients with combined hyperlipidemia: relations with
baseline lipid profiles. Atherosclerosis. Ireland 2003, 170:315-323.
44. Krysiak R, Gdula-Dymek A, Bachowski R, Okopien B: Pleiotropic effects of
atorvastatin and fenofibrate in metabolic syndrome and different types
of pre-diabetes. Diabetes Care. United States 2010, 33:2266-2270.
45. Rosenson RS: Effect of fenofibrate on adiponectin and inflammatory
biomarkers in metabolic syndrome patients. Obesity (Silver Spring). United
States 2009, 17:504-509.
Ye et al. Diabetology & Metabolic Syndrome 2011, 3:24
http://www.dmsjournal.com/content/3/1/24
Page 10 of 1146. Belfort R, Berria R, Cornell J, Cusi K: Fenofibrate reduces systemic
inflammation markers independent of its effects on lipid and glucose
metabolism in patients with the metabolic syndrome. J Clin Endocrinol
Metab. United States 2010, 95:829-836.
doi:10.1186/1758-5996-3-24
Cite this article as: Ye et al.: Short-term effect of fenofibrate on C-
reactive protein: A meta-analysis of randomized controlled trials.
Diabetology & Metabolic Syndrome 2011 3:24.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Ye et al. Diabetology & Metabolic Syndrome 2011, 3:24
http://www.dmsjournal.com/content/3/1/24
Page 11 of 11